Abstract:ABSTRACT Antibodies targeting an envelope dimer epitope (EDE) cross-neutralize Zika virus (ZIKV) and dengue virus (DENV) and have thus inspired an epitope-focused vaccine design. There are two EDE antibody subclasses (EDE1, EDE2) distinguished by their dependence on viral envelope protein N -linked glycosylation at position N153 (DENV) or N154 (ZIKV) for binding. Here, we determined how envelope glycosylation site mutations affect neutralization by EDE and other broadly neutralizing antibodies. Consistent with structural studies, mutations abolishing the N153/N154 glycosylation site increased DENV and ZIKV sensitivity to neutralization by EDE1 antibodies. Surprisingly, despite their location at predicted contact sites, these mutations also increased sensitivity to EDE2 antibodies. Moreover, despite preserving the glycosylation site motif (N-X-S/T), substituting the threonine at ZIKV envelope residue 156 with a serine resulted in loss of glycan occupancy accompanied with increased neutralization sensitivity to EDE antibodies. For DENV, the presence of a serine instead of a threonine at envelope residue 155 retained glycan occupancy, but nonetheless increased sensitivity to EDE antibodies, in some cases to a similar extent as mutation at N153, which abolishes glycosylation. Envelope glycosylation site mutations also increased ZIKV and DENV sensitivity to other non-EDE broadly neutralizing antibodies, but had limited effects on ZIKV- or DENV-specific antibodies. Thus, envelope protein glycosylation is context-dependent and modulates the potency of broadly neutralizing antibodies in a manner not predicted by existing structures. Manipulating envelope protein glycosylation could be a novel strategy for engineering vaccine antigens to elicit antibodies that broadly neutralize ZIKV and DENV. IMPORTANCE Antibodies that potently cross-neutralize Zika (ZIKV) and dengue (DENV) viruses are attractive to induce via vaccination to protect against these co-circulating flaviviruses. Structural studies have shown that viral envelope protein glycosylation is important for binding by one class of these so-called broadly neutralizing antibodies, but less is known about its effect on neutralization. Here, we investigated how envelope protein glycosylation site mutations impact the potency of broadly neutralizing antibodies against ZIKV and DENV. We found that glycan occupancy was not always predicted by an intact N-X-S/T sequence motif. Moreover, envelope protein glycosylation site mutations alter the potency of broadly neutralizing antibodies in a manner unexpected from their predicted binding mechanism as determined by existing structures. We therefore highlight the complex role and determinants of envelope protein glycosylation that should be considered in the design of vaccine antigens to elicit broadly neutralizing antibodies.

Role of glycosylation in enveloped virus infection

Exploitation of glycosylation in enveloped virus pathobiology

Glycosylation of viral proteins: Implication in virus–host interaction and virulence

The Mechanism of Glycosylation in SARS-CoV-2 Infection and Application in Drug Development

Glycosylation is a key in SARS-CoV-2 infection

Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies

The bulky and the sweet: How neutralizing antibodies and glycan receptors compete for virus binding

Role of Protein Glycosylation in Host-Pathogen Interaction

The Glycan‐mediated Mechanism on the Interactions of Gp120 with CD4 and Antibody: Insights from Molecular Dynamics Simulation

Flavivirus Envelope Protein Glycosylation: Impacts on Viral Infection and Pathogenesis

SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity

Glycosylation in SARS-CoV-2 variants: A path to infection and recovery

Defining the impact of flavivirus envelope protein glycosylation site mutations on sensitivity to broadly neutralizing antibodies

Glycan Nanostructures of Human Coronaviruses

The glycosylation in SARS-CoV-2 and its receptor ACE2

Levels of N-linked Glycosylation on the V1 Loop of HIV-1 Env Proteins and Their Relationship to the Antigenicity of Env from Primary Viral Isolates.

Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored Hiv-1 Envelope Glycoprotein Trimers and Soluble Gp140

Site-Specific O-glycosylation of SARS-CoV-2 Spike Protein and Its Impact on Immune and Autoimmune Responses

The glycosylation of immunoglobulin G and its alterations in diseases

Glycosylation in viral hepatitis